Comparative Pharmacology
Head-to-head clinical analysis: PHENYTEX versus PRIMIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYTEX versus PRIMIDONE.
PHENYTEX vs PRIMIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Also enhances GABA-mediated inhibition.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
300-400 mg/day orally in divided doses, typically 100 mg three times daily or 200 mg twice daily; loading dose 1 g orally divided into three doses (400 mg, 300 mg, 300 mg) at 2-hour intervals, or 10-15 mg/kg IV at a rate not exceeding 50 mg/min.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
None Documented
None Documented
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
22 hours (range 7-42 hours; prolonged in hepatic impairment; clinical context: steady-state achieved in 5-7 days)
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Renal (hepatic metabolism to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal excretion minimal)
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Category C
Category D/X
Anticonvulsant
Anticonvulsant